# Effect of DM on Outcomes and Response Rate in Patients With Advanced NSCLC on ICI

> **NCT06100796** · — · UNKNOWN · sponsor: **Assiut University** · enrollment: 60 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer Metastatic
- Diabetes Mellitus

## Interventions

- **COMBINATION_PRODUCT:** Pembrolizumab

## Key facts

- **NCT ID:** NCT06100796
- **Lead sponsor:** Assiut University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-10-01
- **Primary completion:** 2024-06-30
- **Final completion:** 2024-12-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2023-10-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06100796

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06100796, "Effect of DM on Outcomes and Response Rate in Patients With Advanced NSCLC on ICI". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT06100796. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*